It's a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers. Among patients with resectable ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral ...

These best credit cards for low-income earners allow you to earn rewards and take advantage of several benefits without a steep spending requirement or an annual fee.

With a low-limit credit card, you can rest assured that you’ll have access to credit in case of emergency or necessity (such as when you want to rent a car), but you won’t have the temptation of ...

Daiichi Sankyo R&D global head Ken Takeshita said: “Enhertu is the first HER2 directed medicine to demonstrate an improvement in overall survival in a randomised Phase III trial in the second ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

One of the major breakthroughs in the field of breast cancer was a new classification of the disease, called HER2-low, referring to the presence of the human epidermal growth factor receptor 2 protein ...

DESTINY-Gastric04 claims to be the first Phase III trial to evaluate the ADC in HER2-positive advanced gastric cancer. Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu ...

In the trial, Enhertu showed a 38% reduction in the risk of disease progression or death versus chemotherapy (hazard ratio [HR] 0.62; confidence interval [CI] 0.52-0.75; p<0.0001) in patients with ...